Gene-based vaccine strategies against cancer Review Article

In recent years, the characterization of gene-based cancer vaccines has been an important step in the development of different treatment options for human carcinoma. These particular vaccines make use of proteins that are specif ical ly produced at very high levels by tumor ce l l s . These tumor-associated antigens (TAAs) are not only used in diagnostic situations, but also in the development of cancer vaccines . In this review we wi l l focus on two wel l character ized TAAs, carcinoembryonic antigen (CEA) and prostate specific antigen (PSA). The two methods of i n v i v o delivery we will examine are recombinant vaccinia virus and nucleic acid immunization. The TAA gene can be c loned into vaccinia v irus and the viral infection stimulates an adequate immune response in the host. In the case of nucleic acid immunization, DNA constructs encoding for TAAs are direct ly injected into the host and are taken up by i t s ce l l s . The ce l l s express the spec i f ic encoded antigen upon which the immune system acts.

[1]  A. Chalian,et al.  Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine , 1998, Oncogene.

[2]  D. Curiel,et al.  Humoral and cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen , 1998, Gene Therapy.

[3]  A. Chalian,et al.  Modulation of amplitude and direction of in vivo immune responses by co‐administration of cytokine gene expression cassettes with DNA immunogens , 1998, European journal of immunology.

[4]  D. Weiner,et al.  First Human Trial of a DNA-Based Vaccine for the Treatment of HIV-1 Infection: Safety and Host Responses , 1998 .

[5]  J. Schlom,et al.  Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. , 1997, Cancer research.

[6]  A. Chalian,et al.  Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes , 1997, Nature Biotechnology.

[7]  R. Barth,et al.  Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Kim,et al.  In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. , 1997, Journal of immunology.

[9]  M. Tao,et al.  Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2 , 1997, Journal of virology.

[10]  S. Steinberg,et al.  Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine. , 1997, Journal of immunotherapy.

[11]  J. Roth,et al.  Gene therapy for cancer: what have we done and where are we going? , 1997, Journal of the National Cancer Institute.

[12]  D. Johnston,et al.  Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. , 1996, Human gene therapy.

[13]  M. Mitchell,et al.  Therapeutic vaccines for melanoma: progress and problems. , 1996, Trends in biotechnology.

[14]  D. Curiel,et al.  Polynucleotide-mediated immunization therapy of cancer. , 1996, Seminars in oncology.

[15]  D. Curiel,et al.  Selected strategies to augment polynucleotide immunization. , 1996, Gene therapy.

[16]  J. Schlom,et al.  A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate , 1995, International journal of cancer.

[17]  J. Schlom,et al.  Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.

[18]  K. Foon,et al.  Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. , 1995, The Journal of clinical investigation.

[19]  F. Gilliland,et al.  Male genital cancers , 1995, Cancer.

[20]  J. Schlom,et al.  Immune response to a carcinoembryonic antigen polynucleotide vaccine. , 1994, Cancer research.

[21]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[22]  G. Shen,et al.  Cancer Vaccines: The Perspective of the Cancer Immunology Branch, NCI , 1993, Annals of the New York Academy of Sciences.

[23]  Bin Wang,et al.  Gene inoculation generates immune responses against human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[25]  J. Schlom,et al.  Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. , 1992, Cancer research.

[26]  J. Schlom,et al.  Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. , 1992, Journal of the National Cancer Institute.

[27]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[28]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[29]  J. Schlom,et al.  A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA) , 1991, International journal of cancer.

[30]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[31]  K. Watt,et al.  Human prostate-specific antigen: structural and functional similarity with serine proteases. , 1986, Proceedings of the National Academy of Sciences of the United States of America.